Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laetrile-marketer sentenced

This article was originally published in The Tan Sheet

Executive Summary

Christian Brothers Contracting Corp. President Jason Vale was sentenced June 18 to 63 months in prison and three years of supervised release for selling Laetrile, a bogus cancer cure, the U.S. District Court of the Eastern District of N.Y. ruled. Laetrile, also known as amygdalin, vitamin B-17 and "apricot pits," is "a highly toxic product that has not shown any effect on treating cancer," FDA says. Vale was convicted last July of three counts of criminal contempt for violating a 2000 court order to cease sale and promotion of Laetrile (1"The Tan Sheet" July 28, 2003, In Brief)...

You may also be interested in...



Laetrile marketer in contempt

Jason Vale, president of Christian Brothers Contracting, was convicted July21 of three counts of criminal contempt in violation of Title 18 by a federal jury in Brooklyn, New York, FDA announces July 24. A November 2000 court order directed Vale to terminate sale, promotion of Laetrile (amygdalin) (1"The Tan Sheet" Nov. 20, 2000, In Brief). Vale continued to sell the product, touting it as a cure for cancer. FDA notes there is no data supporting the cancer claims and the substance breaks down into cyanide gas once inside the body...

Gilead Wins Breach Of Contract Suit Against CDC But Damages, Patent Dispute Are Unresolved

Court finds government failed to promptly notify Gilead of its PrEP-related patent applications as required under agreements for supply of HIV drugs used in CDC studies. Whether Gilead will have to license government patents remains undecided.

Lunsumio Provides First Test For Korea's Breakthrough Therapy Program

South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel